GLP-1s and PCOS weight loss plateaus: what the data says

What did @haleighweaver5 actually say?

In a short TikTok aimed at people with PCOS using GLP-1 medications, @haleighweaver5 offered four tips to break a weight-loss plateau on what she calls "Zimpik" (likely a mispronunciation of Zepbound or a blend of Zepbound and Ozempic). The advice: rotate injection sites between stomach and thigh, add movement like Pilates or walking, force yourself to eat enough protein even when appetite is suppressed, and drink water with electrolytes. She frames these as proactive steps, not just reactive ones: "start doing this before you hit that plateau."

The video is casual, anecdotal, and clearly not medical advice, but it has 7.8K views targeting a PCOS audience that is actively searching for help with stalled weight loss on GLP-1 drugs. That reach matters when evaluating accuracy.

Does the science back this up?

Mostly, yes, with one significant caveat. Three of the four tips have real evidence behind them. The injection site rotation claim is the outlier, and it is the one she leads with most confidently.

On protein: this is well-supported. GLP-1 receptor agonists suppress appetite, which creates a real risk of inadequate protein intake during caloric restriction. Inadequate protein during weight loss accelerates lean mass loss, which slows resting metabolic rate and can stall fat loss. Churchward-Venne et al. (2012, Nutrition and Metabolism) established that higher protein intakes preserve lean mass during energy restriction. More recently, analyses of semaglutide trials have flagged that roughly 25-40% of weight lost can be lean mass without resistance training and adequate protein intake.

On exercise: the evidence is strong. Resistance training and even moderate walking improve insulin sensitivity independently of weight loss, which matters specifically for the PCOS audience she is addressing. Kirwan et al. (2009, Obesity) found aerobic exercise improved insulin sensitivity significantly in overweight adults.

On electrolytes and water: reasonable but overstated. GLP-1-related nausea and reduced food intake can lower sodium and potassium consumption, and hydration supports metabolic function. The evidence that electrolytes specifically "break" a plateau is thin.

What did they get wrong (or right)?

The injection site rotation claim is the most problematic. She says changing from stomach to thigh "makes a huge difference" for breaking a plateau. This conflates two separate issues: injection site rotation is a real clinical recommendation, but it exists to prevent lipohypertrophy (localized fat buildup from repeated injections), not to alter drug efficacy in a way that breaks weight-loss plateaus.

Pharmacokinetic data on subcutaneous GLP-1 medications does show minor variation in absorption rates between abdominal and thigh sites, but these differences are clinically small and do not translate into meaningful differences in weight loss outcomes. The FDA prescribing information for tirzepatide (Zepbound) recommends rotating sites to avoid injection-site reactions, not to optimize weight loss. There is no peer-reviewed evidence that rotating sites breaks a plateau. Presenting this as the first and most impactful tip is misleading.

What she got right: the protein advice is genuinely useful and underemphasized in popular GLP-1 content. The exercise recommendations are practical and evidence-backed. Telling people "you may not be hungry, but you're going to have to force yourself" to eat enough protein is actually good guidance for GLP-1 users at risk of muscle loss.

What should you actually know?

Weight-loss plateaus on GLP-1 medications are real and documented. A 2022 analysis of the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine) showed tirzepatide produced substantial weight loss, but individual responses vary widely and stalls occur. The reasons are physiological: adaptive thermogenesis, lean mass loss reducing metabolic rate, and behavioral adaptation all play roles.

If you have PCOS, the stakes around muscle mass and insulin sensitivity are higher than average. PCOS is associated with baseline insulin resistance, and losing lean mass during GLP-1 treatment can worsen that picture over time. This makes the protein and resistance training advice from this video genuinely relevant for this specific audience, even if the injection site tip does not hold up.

Rotate your injection sites because your provider recommends it, not because it will restart weight loss. If you are on a GLP-1 medication and have hit a plateau, talk to your prescriber. Dose adjustments, medication switches, and structured dietary support are the evidence-based levers, not injection geography.